H.C. Wainwright initiated coverage of Oruka Therapeutics with a Buy rating and $45 price target Oruka is a clinical stage biotech company developing next-generation biologics aimed at validated targets in inflammation and immunology arenas, the analyst tells investors in a research note. The firm says the company is making validated drugs better, with less frequent dosing.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA: